Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Astellas signs $760mm deal for beta-secretase inhibitors; CTS21166 program terminated; entire deal ended

Executive Summary

CoMentis (formerly Athenagen; focuses on neurovascular disorders) has licensed Astellas Pharma exclusive worldwide rights to its Phase I Alzheimer's disease candidate CTS21166 plus others in its beta-secretase inhibitor program. The companies also agreed to research future molecules in this class.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Royalty or Profit Split Information
    • R+D and Marketing-Licensing
    • Includes Equity

Related Companies

Advertisement
UsernamePublicRestriction

Register